Get the Stockscreener App
137.99
1.02%
-1.45
Neurocrine Biosciences Inc stock is traded at $137.99, with a volume of 83,779.
It is down -1.02% in the last 24 hours and up +8.89% over the past month.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
See More
Previous Close:
$139.44
Open:
$138.07
24h Volume:
83,779
Relative Volume:
0.09
Market Cap:
$13.92B
Revenue:
$2.24B
Net Income/Loss:
$385.90M
P/E Ratio:
74.19
EPS:
1.86
Net Cash Flow:
$440.10M
1W Performance:
+0.75%
1M Performance:
+8.89%
6M Performance:
+0.25%
1Y Performance:
+4.75%
1-Day Range:
$136.96
$138.28
1-Week Range:
$135.84
$139.82
52-Week Range:
$110.95
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
138.07 | 13.92B | 2.24B | 385.90M | 440.10M | 3.73 |
|
ZTS
Zoetis Inc
|
162.01 | 73.09B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.455 | 42.88B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.19 | 41.75B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.25 | 25.06B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.31 | 14.71B | 15.05B | -883.30M | 1.89B | -0.74 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia - Marketscreener.com
Neurocrine Biosciences to Participate at Investor Conferences in December - cnhinews.com
Principal Financial Group Inc. Reduces Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences Stock Sees RS Rating Upgrade - Yahoo! Voices
NBIX: 3 Specialty Pharma Stocks Addressing Unmet Medical Needs - StockNews.com
Q1 EPS Forecast for Neurocrine Biosciences Lifted by Analyst - MarketBeat
Neurocrine Biosciences, Inc. Selects PANTHERx®Rare Specialty Pharmacy for Distribution of Crenessity™ (crinecerfont) - StreetInsider.com
Neurocrine Bio shares expected to grow with robust U.S. sales forecast for Crenessity - Investing.com UK
Neurocrine Biosciences (NASDAQ:NBIX) Receives "Overweight" Rating from Piper Sandler - MarketBeat
Barclays Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $165.00 - MarketBeat
Sanctuary Advisors LLC Buys 3,898 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
BofA raises Neurocrine Bio target to $182 on drug launch By Investing.com - Investing.com Canada
What Analysts Are Saying About Neurocrine Biosciences Stock - Benzinga
Neurocrine Biosciences launches Crenessity in USA - The Pharma Letter
Needham & Company LLC Reiterates Hold Rating for Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat
Neurocrine launches CRENESSITY for adrenal hyperplasia in US By Investing.com - Investing.com South Africa
Neurocrine Bioscience’s CRENESSITY Becomes Commercially Available In The U.S. - Contract Pharma
Neurocrine Biosciences (NBIX) Announces Commercial Availability of CRENESSITY for Children and Adults With Classic Congenital Adrenal Hyperplasia - StreetInsider.com
Neurocrine launches CRENESSITY for adrenal hyperplasia in US - Investing.com
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia - PR Newswire
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Ingrid Delaet Sells 1,091 Shares - MarketBeat
Neurocrine Biosciences chief regulatory officer sells $147,285 in shares - Investing.com
Neurocrine Biosciences chief regulatory officer sells $147,285 in shares By Investing.com - Investing.com UK
Neurocrine Biosciences' SWOT analysis: stock outlook mixed amid pipeline setbacks - Investing.com Canada
Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth - Seeking Alpha
Tidal Investments LLC Acquires 5,197 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
HighTower Advisors LLC Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine wins FDA OK for first-in-class CAH drug - The Pharma Letter
Franklin Resources Inc. Sells 144,114 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
FDA Tracker: Neurocrine, Checkpoint Score FDA Approvals - BioSpace
Neurocrine’s First New CAH Treatment in 70 Years Gets FDA Approval - geneonline
Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder - MedCity News
Neurocrine’s Crenessity Is The First New Drug For CAH In 70 Years - News & Insights
Blockbuster bound? Neurocrine’s hyperplasia drug approved - BioWorld Online
Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug - Yahoo! Voices
Neurocrine Biosciences (NASDAQ:NBIX) Trading 5% HigherHere's What Happened - MarketBeat
Novo builds up manufacturing; Pepgen Duchenne trial put on hold - BioPharma Dive
Neurocrine Biosciences rises on FDA nod for CAH drug By Investing.com - Investing.com Australia
Neurocrine Biosciences rises on FDA nod for CAH drug - Investing.com
Neurocrine Biosciences (NASDAQ:NBIX) Receives "Outperform" Rating from William Blair - MarketBeat
FDA clears Neurocrine drug for rare adrenal disorder - pharmaphorum
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential - Yahoo Finance
Wedbush Reiterates Outperform Rating for Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences' (NBIX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Goldman Sachs lifts Neurocrine Bio shares target, buy rating on FDA approval - Investing.com Canada
Launch complexities temper expectations for Neurocrine Bio stock, says BMO Capital - Investing.com Australia
Geode Capital Management LLC Increases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
(NBIX) Technical Data - Stock Traders Daily
Public Employees Retirement System of Ohio Sells 6,046 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
NEUROCRINE BIOSCIENCES INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):